Combined Targeting of the Epidermal Growth Factor Receptor and Cyclooxygenase-2 Pathways
Open Access
- 1 September 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (17) , 6097-6099
- https://doi.org/10.1158/1078-0432.ccr-05-1217
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Tumor Growth Inhibition by Simultaneously Blocking Epidermal Growth Factor Receptor and Cyclooxygenase-2 in a Xenograft ModelClinical Cancer Research, 2005
- E-cadherin Suppression Accelerates Squamous Cell Carcinoma Progression in Three-Dimensional, Human Tissue ConstructsCancer Research, 2005
- 15-Hydroxyprostaglandin Dehydrogenase Is Down-regulated in Colorectal CancerJournal of Biological Chemistry, 2005
- Cyclooxygenase-2 and Epidermal Growth Factor Receptor: Pharmacologic Targets for ChemopreventionJournal of Clinical Oncology, 2005
- NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancerCarcinogenesis: Integrative Cancer Research, 2004
- Prostaglandin E2 Regulates Cell Migration via the Intracellular Activation of the Epidermal Growth Factor ReceptorJournal of Biological Chemistry, 2003
- Prostaglandin E2 stimulates colon cancer cell growth through induction of amphiregulinGastroenterology, 2003
- High-Throughput Tissue Microarray Analysis Used to Evaluate Biology and Prognostic Significance of the E-Cadherin Pathway in Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2002
- Gross Genomic Aberrations in Precancers: Clinical Implications of a Long-Term Follow-Up Study in Oral ErythroplakiasJournal of Clinical Oncology, 2002
- Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2Cell, 1995